SPATS2L Inhibitors
Chemical inhibitors of SPATS2L target various signaling pathways in which this protein is involved, each employing a distinct mechanism of action to inhibit its function. Wortmannin and LY294002 are two such inhibitors that directly target phosphoinositide 3-kinases (PI3K), pivotal enzymes in the PI3K/AKT signaling pathway. By inhibiting PI3K, these chemicals reduce AKT phosphorylation and prevent downstream processes where SPATS2L is functionally relevant. Similarly, Rapamycin exerts its inhibitory effect by targeting mTOR, another key protein in the PI3K/AKT pathway, which indirectly leads to the inhibition of SPATS2L's associated functions. On a different pathway, U0126 and PD98059 focus on the MAPK/ERK cascade by inhibiting MEK, thus preventing the activation of ERK, a kinase that would typically engage SPATS2L in signal transduction related to cell proliferation and differentiation.
Inhibition of SPATS2L also involves obstructing signaling through p38 MAPK and JNK, both of which are part of the MAP kinase family and influence processes that include SPATS2L. SB203580 specifically inhibits p38 MAPK, while SP600125 targets JNK, both leading to a cessation of SPATS2L activity within these pathways. Src family kinases, which are implicated in various cellular processes, are inhibited by PP2 and Dasatinib, thereby disrupting SPATS2L's role in those signaling pathways. PF-562271 targets focal adhesion kinase (FAK), which affects cell adhesion and migration processes that SPATS2L is believed to be involved in. Y-27632, by inhibiting ROCK, affects the actin cytoskeleton organization and subsequent signaling activities where SPATS2L may play a role. Lastly, ZM-447439 inhibits Aurora kinases, which are crucial for mitosis, a process in which SPATS2L has been implicated, thus preventing SPATS2L's involvement in cell division. Each of these inhibitors, by acting on specific enzymes and kinases, effectively reduces the functional activity of SPATS2L in various cellular signaling pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. SPATS2L has been found to be involved in PI3K/AKT signaling. By inhibiting PI3K, Wortmannin can reduce AKT phosphorylation and activity, which in turn would inhibit SPATS2L function by preventing its participation in this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, like Wortmannin. It inhibits the PI3K/AKT pathway, which is connected to the function of SPATS2L. Inhibition of PI3K leads to a decrease in AKT activity, thereby inhibiting the downstream effects that would require the functional involvement of SPATS2L. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is a downstream component of the PI3K/AKT pathway, where SPATS2L is involved. By inhibiting mTOR, Rapamycin can suppress the mTOR signaling pathway, leading to an inhibition of SPATS2L function as it is part of the downstream signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway. SPATS2L has been linked to this signaling pathway. By inhibiting MEK, U0126 prevents the activation of ERK, which would be necessary for the functional activity of SPATS2L in this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. SPATS2L is implicated in pathways involving MAP kinases. By inhibiting p38 MAPK, SB203580 would block the signaling that necessitates SPATS2L function, leading to its inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is upstream in the MAPK/ERK pathway involving SPATS2L. By blocking MEK, PD98059 inhibits the activation of ERK and subsequently inhibits the function of SPATS2L linked to this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, another member of the MAP kinase family, which is involved in pathways associated with SPATS2L. Inhibition of JNK signaling by SP600125 can lead to the functional inhibition of SPATS2L by preventing its action within this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. SPATS2L has been implicated in tyrosine kinase signaling pathways. By inhibiting Src kinases, PP2 would prevent downstream signaling that requires the involvement of SPATS2L, thereby functionally inhibiting it. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases, which are related to pathways involving SPATS2L. Inhibition of these kinases by Dasatinib would disrupt the associated signaling pathways, thus functionally inhibiting SPATS2L. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $312.00 $474.00 $1124.00 | 3 | |
PF-562271 is a focal adhesion kinase (FAK) inhibitor. SPATS2L has been implicated in cell adhesion and migration processes that involve FAK signaling. By inhibiting FAK, PF-562271 would impair the signaling required for SPATS2L to exert its function in these processes. | ||||||